Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

AstraZeneca pauses coronavirus vaccine trial, shares slip on rollout doubts

Published 09/09/2020, 08:09 AM
Updated 09/09/2020, 02:01 PM
© Reuters. FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the NYSE in New York

© Reuters. FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the NYSE in New York

By Ludwig Burger

LONDON (Reuters) - AstraZeneca's (L:AZN) suspension of global trials of its experimental coronavirus vaccine after an unexplained illness in a study subject in Britain has cast doubt on prospects for an early rollout.

The vaccine, which Britain's AstraZeneca is developing with the University of Oxford, has been described by the World Health Organization as probably the world's leading candidate and the furthest developed.

AstraZeneca said on Tuesday it had paused trials, including late-stage ones, to allow an independent committee to review safety data, and it was working to minimise any potential impact on the timeline.

"It is obviously a challenge to this particular vaccine trial," Britain's Health Secretary Matt Hancock told Sky News.

The patient was suffering from neurological symptoms associated with a rare spinal inflammatory disorder called transverse myelitis, said Chief Executive Pascal Soriot, according to Stat News, citing investors who had listened to a call it said was organised by J.P. Morgan.

The diagnosis has yet to be confirmed, but the patient is recovering and will likely be discharged from the hospital soon, the CEO reportedly added.

The pause follows reports that the United States was aiming for fast-track authorization or approval before November's presidential election.

© Reuters. FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the NYSE in New York

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.